COVID-19
Infectious disease · 2022–2026
5decisions
5medicines
3carried consumer input
5individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mRNA-1273 Prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in adults aged 75 years or more (2 doses per year), adults aged 65-74 years (1 dose per… | Mar 2026 | Deferred | no section in document |
| raxtozinameran Prevention of COVID-19 disease caused by SARS-CoV-2 in adults aged ≥18 years at increased risk of severe COVID-19 disease, as booster vaccination (annual or… | Dec 2025 | Recommended | 1 individuals |
| molnupiravir Treatment of patients with mild to moderate COVID-19 who are at high risk of severe disease requiring hospitalisation, including those aged ≥70 years, those… | Nov 2023 | Recommended with restriction | 1 individuals Kirby Institute · Lung Foundation Australia · Immunisation Coalition |
| nirmatrelvir and ritonavir Treatment of mild to moderate COVID-19 in patients at high risk of severe disease requiring hospitalisation, including persons aged ≥70 years,… | Nov 2023 | Recommended with restriction | 3 individuals Lung Foundation Australia · Rare Cancers Australia |
| tixagevimab and cilgavimab Pre-exposure prophylaxis (PrEP) of COVID-19 in adults and adolescents aged 12 years and older who are severely immunocompromised or in whom vaccination with… | Sep 2022 | Not recommended | no section in document |
Who spoke
Lung Foundation Australia · Kirby Institute · Immunisation Coalition · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.